WuXi PharmaTech (Cayman), Inc. (ADR) (NYSE:WX)
China-based pharmaceutical and biotechnology R&D outsourcing company which provides a integrated portfolio of laboratory and manufacturing services in the drug discovery and development process to pharmaceutical and biotechnology companies.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
tomfoolme
(< 20)
Submitted: 1/13/2012 1:26:46 AM :
Start Price:
$12.00
WX Score:
+9.72
china - biotechnology R&D outsourcing with a portfolio of laboratory and manufacturing services.
no div
Total Debt / Equity 0.15
Price Earnings 9.60
Price/Sales 2.40
Price/Book 1.98
Price/Cash Flow 6.90
Recs
StockDocStan
(< 20)
Submitted: 9/7/2011 12:06:41 PM :
Start Price:
$13.08
WX Score:
-7.77
Cmon, we can't hate all things Chinese, at least not if they do it cheaper and make US more money in the process!!! How can this stock not be $20-plus now on valuation alone???
Recs
mshiney77
(71.59)
Submitted: 7/7/2011 4:43:32 PM :
Start Price:
$16.62
WX Score:
-17.97
It has a strong balance sheet and has the growing Chinese market. Plus, the population is aging in the developed world...this could be a huge one.
Recs
GUOCHONGHUA
(35.88)
Submitted: 7/7/2011 6:48:27 AM :
Start Price:
$16.79
WX Score:
-17.81
Intrinsic:10.46
Recs
gwanoy
(< 20)
Submitted: 4/26/2010 10:06:55 PM :
Start Price:
$19.15
WX Score:
-39.82
high quality, inexpensive pharmaceutical R&D.
Recs
jmt587
(99.87)
Submitted: 9/28/2009 3:00:37 PM :
Start Price:
$12.00
WX Score:
-12.37
Chinese BioTech & Pharma Outsourcing company.
Recs
oxdeming
(45.61)
Submitted: 9/11/2009 4:38:13 AM :
Start Price:
$11.55
WX Score:
-9.97
China pharm is in the rising
Recs
pslorenz
(97.93)
Submitted: 4/6/2009 1:00:32 PM :
Start Price:
$4.95
WX Score:
+112.53
Outsourcing is and will continue to be a hot ticket item. Outsourcing pharma R&D is an interesting concept.
Recs
Recs
TMFBreakerThiel
(93.43)
Submitted: 1/13/2009 4:35:04 PM :
Start Price:
$7.00
WX Score:
+35.99
I like the CRO business (contract research...not drug development, as some seem to think) as a secular trend, and WuXi is the lower-cost Chinese solution. Perhaps not the greatest business moat, but at this price, I'll take the risk.
Recs
ironyworks
(77.77)
Submitted: 1/1/2009 2:17:22 AM :
Start Price:
$8.00
WX Score:
+20.07
Chinese medical services
Recs
tskephart
(37.07)
Submitted: 11/26/2008 12:30:32 PM :
Start Price:
$5.97
WX Score:
+70.65
Pharmaceutical R&D is a very expensive part of the pharmaceutical market. I feel their will be a paradigm shift on how global pharmaceutical companies approach research, one of the results will be more outsourcing and collaborations.. WuXi is positioned well to take advantage of this shift.
Recs
lwc123
(72.67)
Submitted: 10/23/2008 12:39:55 PM :
Start Price:
$7.07
WX Score:
+38.86
8x trailing EBITDA. 75% earnings growth. Market leader in China. Outsourcing is a natural in down markets. The pharma customer base is steady in a down market. Good risk-reward.
Recs
deafdumbnblind
(< 20)
Submitted: 10/22/2008 7:23:07 PM :
Start Price:
$7.50
WX Score:
+30.31
excellent company, great growth....PE 6.21 get some balls and buy !
Recs
EagleTraderOne
(< 20)
Submitted: 9/10/2008 5:04:13 PM :
Start Price:
$15.77
WX Score:
+26.66
Still a way to go...down. Not a buy...yet.
Recs
Recs
j1e1k1
(89.83)
Submitted: 6/7/2008 9:57:13 AM :
Start Price:
$19.69
WX Score:
-32.08
No-brainer.
Booming industry in booming country at a great price!
Recs
stockgaucho
(< 20)
Submitted: 5/27/2008 11:44:04 PM :
Start Price:
$22.23
WX Score:
-38.61
For some reason I foresee this first quarter doubled profit company performing well in the future.
Recs
deuspecuniae
(96.04)
Submitted: 5/1/2008 12:11:17 PM :
Start Price:
$17.77
WX Score:
-22.72
The looming recession that bernanke and the whole federal reserve gang have set this country towards will send alot of investors into the pharmaceutical's sector--being the traditional recessionary savior to say the least. Plus, most pharmaceutical stocks have been beaten down this past winter, and I see a reversal across the entire sector. Also, those companies already on a run will continue due to the upward momentum this summer from key reversals and upgrades throughout the sector.
Recs
EJDoran
(73.85)
Submitted: 3/28/2008 1:56:17 PM :
Start Price:
$22.30
WX Score:
-44.06
While the Chinese market is open, someone has to be the top dog in the Chinese pharma market and my bet is on these guys. Well run, low costs in a usually high cost sector, huge and growing market.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 40 : 1 2 Next »